{"nctId":"NCT00464672","briefTitle":"Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old","startDateStruct":{"date":"2007-04"},"conditions":["Influenza"],"count":1893,"armGroups":[{"label":"Influenza virus vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: Influenza virus vaccine"]},{"label":"Comparator influenza vaccine","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator influenza vaccine"]}],"interventions":[{"name":"Influenza virus vaccine","otherNames":[]},{"name":"Comparator influenza vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy subjects 3 to 64 years of age\n\nExclusion Criteria:\n\n* Receipt of other investigational products within 3 months or other vacine within 1 month;\n* Allergy to eggs, egg products, or any other vaccine component;\n* Laboratory confirmed influenza disease within 6 months;\n* Have previously received an influenza vaccination (3 to 8 years only);","healthyVolunteers":true,"sex":"ALL","minimumAge":"3 Years","maximumAge":"64 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With Seroprotection, in Healthy Adults 18 to 64 Years of Age","description":"To evaluate immunogenicity, measured by seroprotection (percentage of subjects achieving a hemagglutination inhibition \\[HI\\] titer ≥40) after one injection of the investigational influenza virus vaccine, administered to healthy adults 18 to 64 years of age. The CBER Guidance states that the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroprotection meet or exceed 70%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"91","spread":null},{"groupId":"OG003","value":"99","spread":null},{"groupId":"OG004","value":"100","spread":null},{"groupId":"OG005","value":"86","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Achieving a Seroconversion Rate, in Adults 18 to 64 Years of Age","description":"Seroconversion rate is defined as percentage of subjects achieving seroconversion (defined as negative pre-vaccination serum \\[HI\\<10\\]/ post-vaccination HI titer ≥40) or significant increase defined as at least a 4-fold increase). According to the CBER Guidance, the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconverion/significant increase meet or exceed 40%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"77","spread":null},{"groupId":"OG003","value":"86","spread":null},{"groupId":"OG004","value":"89","spread":null},{"groupId":"OG005","value":"74","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local and Systemic Symptoms in Adults 18 to 64 Years of Age","description":"Solicited local and systemic reactions were assessed after vaccination in adults 18 to 64 years of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Seroprotection, in Healthy Children/Adolescents 9 to 17 Years of Age","description":"To descriptively evaluate immunogenicity, measured by seroprotection rate (percentage of subjects achieving a hemagglutination inhibition \\[HI\\] titer ≥40) after one injection of investigational influenza virus vaccine, administered to healthy children/adolescents 9 to 17 years of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"93","spread":null},{"groupId":"OG003","value":"98","spread":null},{"groupId":"OG004","value":"100","spread":null},{"groupId":"OG005","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving Seroconversion Rate, in Healthy Children/Adolescents 9 to 17 Years of Age","description":"Seroconversion rate is defined as percentage of subjects achieving seroconversion (defined as negative pre-vaccination serum \\[HI\\<10\\]/ post-vaccination HI titer ≥40) or significant increase (defined as at least a 4-fold increase) after one injection of the investigational influenza virus vaccine, administered to healthy children/adolescents 9 to 17 years of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"81","spread":null},{"groupId":"OG003","value":"91","spread":null},{"groupId":"OG004","value":"92","spread":null},{"groupId":"OG005","value":"73","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs), in Healthy Children/Adolescents 9 to 17 Years of Age","description":"To evaluate immunogenicity measured by GMTs after one injection of investigational influenza virus vaccine, administered to healthy children/adolescents 9 to 17 years of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"960","spread":null},{"groupId":"OG001","value":"493","spread":null},{"groupId":"OG002","value":"144","spread":null},{"groupId":"OG003","value":"1246","spread":null},{"groupId":"OG004","value":"1463","spread":null},{"groupId":"OG005","value":"114","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local and Systemic Symptoms in Children/Adolescents 9 to 17 Years of Age","description":"Solicited local and systemic reactions were assessed after vaccination in children/adolescents 9 to 17 years of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Seroprotection, in Healthy Children 3 to 8 Years of Age","description":"To descriptively evaluate immunogenicity, measured by seroprotection rate (percentage of subjects achieving a hemagglutination inhibition \\[HI\\] titer ≥40) after two injections of the investigational influenza virus vaccine, in healthy children 3 to 8 years of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"85","spread":null},{"groupId":"OG003","value":"99","spread":null},{"groupId":"OG004","value":"99","spread":null},{"groupId":"OG005","value":"81","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving Seroconversion Rate, in Healthy Children 3 to 8 Years of Age","description":"Seroconversion rate is defined as percentage of subjects achieving seroconversion (defined as negative pre-vaccination serum \\[HI\\<10\\]/ post-vaccination HI titer ≥40) or significant increase (defined as at least a 4-fold increase) after two injections of the investigational influenza virus vaccine, in healthy children 3 to 8 years of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"83","spread":null},{"groupId":"OG003","value":"97","spread":null},{"groupId":"OG004","value":"95","spread":null},{"groupId":"OG005","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs), in Healthy Children 3 to 8 Years of Age","description":"To evaluate immunogenicity measured by GMTs after two injections of the investigational influenza virus vaccine, in healthy children 3 to 8 years of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"625","spread":null},{"groupId":"OG001","value":"710","spread":null},{"groupId":"OG002","value":"157","spread":null},{"groupId":"OG003","value":"716","spread":null},{"groupId":"OG004","value":"1472","spread":null},{"groupId":"OG005","value":"126","spread":null}]}]}]},{"type":"SECONDARY","title":"Number or Subjects Reporting Solicited Local and Systemic Symptoms, in Healthy Children 3 to 8 Years of Age.","description":"Solicited local and systemic reactions were assessed after each vaccination, in healthy children 3 to 8 years of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"57","spread":null},{"groupId":"OG003","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"41","spread":null},{"groupId":"OG003","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs), in Healthy Adults 18 to 64 Years of Age","description":"Immunogenicity measured by GMTs after one injection of the investigational influenza virus vaccine, in healthy adults 18 to 64 years of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"244","spread":null},{"groupId":"OG001","value":"219","spread":null},{"groupId":"OG002","value":"126","spread":null},{"groupId":"OG003","value":"512","spread":null},{"groupId":"OG004","value":"485","spread":null},{"groupId":"OG005","value":"104","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":460},"commonTop":["Injection Site Pain","Headache","Myalgia","Malaise","Fatigue"]}}}